LSL Pharma Group Inc.
LSL.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 24.95% | -81.56% | 40.62% | 38.43% | 26.40% |
| Total Depreciation and Amortization | 2.61% | 2.10% | 37.92% | -30.58% | 20.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -39.11% | 66.60% | 278.78% | -159.82% | 9.91% |
| Change in Net Operating Assets | 25.98% | 71.00% | -415.99% | 80.85% | -763.89% |
| Cash from Operations | 18.41% | 94.48% | -99.84% | 60.82% | -27,105.97% |
| Capital Expenditure | -29.16% | -68.55% | -164.16% | 552.63% | 18.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 98.57% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.52% | -37.03% | 25.36% | -680.11% | -151.35% |
| Cash from Investing | 56.83% | -362.94% | -205.86% | 406.87% | 11.98% |
| Total Debt Issued | 300.68% | -65.18% | 1,449.26% | -97.24% | 251.86% |
| Total Debt Repaid | 18.07% | -165.45% | -147.49% | 661.58% | 53.39% |
| Issuance of Common Stock | -81.84% | 166.25% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 54.67% | -262.86% | 63.06% | 2.46% | -41.37% |
| Cash from Financing | -62.92% | 41.21% | 649.33% | -83.77% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -138.93% | 874.01% | -213.01% | 106.62% | -136.22% |
